New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export JNJ’s income statement to Excel — free account
Johnson & Johnson
JNJHealthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
270.19
3.09
+1.16%
Follow JNJ
Alert me
Johnson & Johnson 8-K filed Oct 14, 2025
2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.